To study heterogeneity in SARS-CoV-2 IgG response titre in patients recovered from COVID-19

https://doi.org/10.4081/monaldi.2021.1943

Authors

  • Avneet Garg | dravneetgarg@gmail.com Department of Respiratory Medicine, Adesh institute of Medical Sciences and Research, Bathinda, Punjab, India. https://orcid.org/0000-0003-0962-9748
  • Rakendra Singh Department of Medicine, Adesh institute of Medical Sciences and Research, Bathinda, Punjab, India.
  • Hariharan Iyer Department of Pulmonary Medicine, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Mansimranjit Kaur Department of Respiratory Medicine, Adesh institute of Medical Sciences and Research, Bathinda, Punjab, India.
  • Surbhi Surbhi Department of Medicine, Adesh institute of Medical Sciences and Research, Bathinda, Punjab, India.
  • Ashish Jindal Department of Medicine, Adesh institute of Medical Sciences and Research, Bathinda, Punjab, India.
  • Saranpal Singh Department of Biochemistry, Adesh institute of Medical Sciences and Research, Bathinda, Punjab, India.
  • Avtar Singh Bansal Department of Community Medicine, Adesh institute of Medical Sciences and Research, Bathinda, Punjab, India.
  • Hem C. Sati Department of Biostatics, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Vinita Jindal Department of Radiology, Adesh institute of Medical Sciences and Research, Bathinda, Punjab, India.

Abstract

The COVID-19 pandemic caused a serious health challenge to the entire mankind. The association between clinical characteristics of disease and formation of neutralizing antibodies have not well studied. A prospective study was conducted for patients recovered from confirmed SARS-CoV-2 infections from 1st August 2020 to 28th February 2021, to study the association between SARS-CoV-2 IgG antibody response titres and clinical characteristics of the disease. A total 92 patients were included in the study. Median age was 52 years; majority were male and middle or old aged.  About 48% patients required hospitalization and 38.3% had moderate CT severity score. Positive SARS-CoV-2-IgG was detected in all patients except one. On comparing the antibody titres among various sub-groups of COVID-19 recovered patients, old age was the only factor associated with statistically significant higher antibody response (28 AU/ml for age<35 years, 53 AU/ml for age group 35-60, and 71 AU/ml for age group >60 years, p value=0.01). Severity of infection, worse CT severity scores, need of hospitalization, oxygen or ventilatory support were associated with higher antibody titres but were not statistically significant. There was a strong correlation of antibody titres when analysed for age of study population (Spearman correlation=0.39, p value <0.001); whereas a weak correlation (Spearman correlation=0.03, p value 0.753) was seen when analysed for CT severity score. Elderly patients had higher antibody titre after recovery from Covid-19 infection. Severity of disease, need of hospitalisation or oxygen/mechanical ventilation did not influence the antibody titre.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

Mojtabavi H, Saghazadeh A, Rezaei N. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis. Eur Cytokine Netw 2020;31:44–9.

Lumley SF, Wei J, O’Donnell D, et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. Clin Infect Dis 2021;73:e699-709.

Ministry of Health [Internet]. Indian guideline for covid 19 severity - Yahoo India Search Results. Accessed: 2021 Mar 30. Available from: https://in.search.yahoo.com/search?fr=mcafee&type=E211IN826G0&p=Ministry+of+health+Indian+guideline+for+covid+19+severity

Pan F, Ye T, Sun P, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology 2020;295:715–21.

Woo MS, Steins D, Häußler V, et al. Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients. J Neurol 2021;268:5-7.

Kowitdamrong E, Puthanakit T, Jantarabenjakul W, et al. Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. PLoS One 2020;15:e0240502.

Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis 2020;71:2027–34.

Chen W, Zhang J, Qin X, et al. SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia. Biomed Pharmacother 2020;130:110629.

Peiris JSM, Chu CM, Cheng VCC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361:1767–72.

Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 2019;4:e123158.

Klein SL, Pekosz A, Park H-S, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Inves. 2020;130:11.

Mehew J, Johnson R, Roberts D, Harvala H. Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020. Euro Surveill 2020;25:2001754.

Downloads

Published
2021-09-28
Info
Issue
Section
COVID-19 - Collection of articles on the Coronavirus outbreak
Supporting Agencies
None
Keywords:
COVID-19, SARS-CoV-2-IgG antibodies, CT severity score, age
Statistics
  • Abstract views: 135

  • PDF: 104
How to Cite
Avneet Garg, Rakendra Singh, Hariharan Iyer, Mansimranjit Kaur, Surbhi Surbhi, Ashish Jindal, Saranpal Singh, Avtar Singh Bansal, Hem C. Sati, and Vinita Jindal. 2021. “To Study Heterogeneity in SARS-CoV-2 IgG Response Titre in Patients Recovered from COVID-19”. Monaldi Archives for Chest Disease, September. https://doi.org/10.4081/monaldi.2021.1943.